{"id":748750,"date":"2025-06-23T17:40:02","date_gmt":"2025-06-23T17:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=748750"},"modified":"2025-06-23T17:40:02","modified_gmt":"2025-06-23T17:40:02","slug":"postpartum-depression-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-sage-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postpartum-depression-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-sage-therapeutics_748750.html","title":{"rendered":"Postpartum Depression Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Sage Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/06\/1750664056.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Postpartum Depression Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Sage Therapeutics\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/06\/1750664056.jpg\" alt=\"Postpartum Depression Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Sage Therapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Postpartum Depression Pipeline Analysis<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cPostpartum Depression &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">Postpartum Depression Pipeline constitutes 2+ key companies continuously working towards developing 2+ Postpartum Depression treatment therapies, analyzes DelveInsight.<\/p>\n<p style=\"text-align: justify;\">Postpartum Depression Overview:<\/p>\n<p style=\"text-align: justify;\">The birth of a child can trigger a wide spectrum of strong emotions, ranging from joy and excitement to anxiety and fear. It&#8217;s common for new mothers to experience the &#8220;baby blues&#8221; shortly after giving birth, which may involve mood swings, crying spells, restlessness, and sleep disturbances. These symptoms usually appear within two to three days post-delivery and often resolve within two weeks. However, some women may face a more intense and longer-lasting condition known as postpartum depression. In rare instances, a severe mental health condition called postpartum psychosis can also develop. Postpartum depression is not a reflection of personal weakness or failure; rather, it is a medical complication associated with childbirth.<\/p>\n<p style=\"text-align: justify;\">&#8220;Postpartum Depression Pipeline Insight 2024&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postpartum Depression Therapeutics Market.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a postpartum depression pipeline sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Postpartum Depression Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s Postpartum Depression pipeline report reveals a developing landscape with over two active companies working on more than two investigational therapies for the condition.<\/p>\n<\/li>\n<li>\n<p>Leading companies like Sage Therapeutics and others are exploring innovative treatment options to enhance care for postpartum depression.<\/p>\n<\/li>\n<li>\n<p>Notable pipeline candidates currently in various stages of development include Zuranolone and additional emerging therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Postpartum Depression Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the key companies that are developing therapies in the Postpartum Depression Market.<\/p>\n<\/li>\n<li>\n<p>The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression treatment.<\/p>\n<\/li>\n<li>\n<p>It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postpartum Depression market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for detailed insights into our postpartum depression pipeline insights report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Postpartum Depression Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Approximately two major companies are focused on developing treatments for postpartum depression. Among them, Sage Therapeutics and others have drug candidates that are in the mid to late stages of development, specifically in Phase III clinical trials.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 22+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Postpartum Depression Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Postpartum Depression Therapies and Key Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Postpartum Depression Clinical Trials and advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Postpartum Depression Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Postpartum Depression Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Postpartum Depression By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Postpartum Depression Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Postpartum Depression Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Download Postpartum Depression Sample report to know in detail about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Postpartum Depression treatment market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Postpartum Depression Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Postpartum Depression &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Postpartum Depression Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Postpartum Depression Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Postpartum Depression Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Postpartum Depression Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Postpartum Depression Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Postpartum Depression Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Postpartum Depression Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Postpartum Depression Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Postpartum Depression Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get Detailed Insights About the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/postpartum-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Postpartum Depression Pipeline Reports Offerings<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=postpartum-depression-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-sage-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=postpartum-depression-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-sage-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Postpartum Depression Pipeline Analysis DelveInsight\u2019s, \u201cPostpartum Depression &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/postpartum-depression-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-sage-therapeutics_748750.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-748750","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/748750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=748750"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/748750\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=748750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=748750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=748750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}